Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. - Wikidata - awgldk - TriplyDB

Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer.

Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer.

http://www.wikidata.org/entity/Q34527500

about

Bispecific antibodies and their applications Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer Catumaxomab: clinical development and future directions Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion Cancer therapy with bispecific antibodies: Clinical experience.Have we overestimated the benefit of human(ized) antibodies?Monoclonal TCR-redirected tumor cell killing.Present and future evolution of advanced breast cancer therapy.Treating breast cancer in the 21st century: emerging biological therapies Testing for HER2 in Breast Cancer: A Continuing Evolution.Editors' pick 2010.New Immunotherapy Strategies in Breast Cancer.Targeting the function of the HER2 oncogene in human cancer therapeutics.Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody.Combining targeted therapies: practical issues to consider at the bench and bedside.Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance.Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer.Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers.Advances in first-line treatment for patients with HER-2+ metastatic breast cancer.Resistance to Trastuzumab in Breast Cancer.Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment.Potential of the trifunctional bispecific antibody surek depends on dendritic cells: rationale for a new approach of tumor immunotherapy.Novel antibodies as anticancer agents.A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis.Use of antibodies and immunoconjugates for the therapy of more accessible cancers.Targeting T cells with bispecific antibodies for cancer therapy The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis.A new class of bispecific antibodies to redirect T cells for cancer immunotherapy.HER2 as a target for breast cancer therapy.Engineered proteins pull double duty.Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trends.Bispecific antibodies for cancer therapy.Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma.Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity.Antibody-based cancer therapy.Development and prospects for bispecific antibody-based therapeutics in cancer and other applications.Multi-specific antibodies for cancer immunotherapy.Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.

P2860

Q26774024-0CFBE496-33A7-4DD4-80CD-F1AEDF6A959A Q28235980-C9E7B7F6-E9F0-4686-805F-18E27B9CE501 Q28274519-58F46F71-D893-4401-85BE-7BF9C6EA9918 Q28296706-6704393E-8851-4BCF-BEB4-99893D8CC696 Q34118856-151F2931-1D70-4B7F-9264-62B126A2060C Q34142714-339DB1E3-38AE-4991-83DB-1A8D9A15AB3E Q34273053-311FFC4F-FC94-4CC3-A56D-2D6EEBC55A0E Q34274925-E3EDFF92-4357-4EBF-A04A-6B9897F8ABF9 Q34326536-4DF5B247-9CCD-41C5-8E28-680D95CC6D89 Q34424285-EC76DFC0-212D-4B59-91E9-EF99E6C29872 Q34476042-AEE365C6-DCAB-49E2-A05A-B3DFFAAC49CC Q34549227-2EE3099E-E7B2-4DB0-A118-A9EF513619CC Q34766486-CDB632E0-9D8B-4FF3-B33E-D02350D77B5C Q35005791-00F39112-631F-4DEB-B9EC-B010FE9D8906 Q35583672-59F0F942-4985-40E9-8398-FD9789AE93D2 Q35624814-61624884-B5A6-4F10-B096-84AB5D2F4330 Q35780315-040522A7-AD45-421A-959B-2C4183B9B421 Q35822172-665951FA-C6A9-470A-8576-6421EDCF4717 Q35989963-77266A32-62C5-4B9F-A446-F44B4E9026BB Q36318226-6FFBBACB-943A-41E7-9F9D-E6E61FD96B7C Q36402698-E07564AB-BD7C-474E-9C50-7A6DAF12F571 Q36785721-09E4E1D4-724F-41AD-8DB0-7A8410608ACA Q36821533-E4471F8B-458B-4D9E-9421-240547186930 Q36832141-BA2FC635-1DEA-4F3F-B017-08DB235A8B48 Q37076922-C795DA2B-7C01-4F1D-9BE0-9CC644C2E8C5 Q37102182-A7C6EF55-5E36-4C0A-83AF-2CF06F619EC2 Q37174938-BF3E2466-1DE6-4A42-9729-57EB97ECDA8F Q37220742-587410A2-6B5E-4D47-AC4B-57FB31A7C049 Q37376013-6E199A91-3F81-4660-B8CA-CC6C86DF560E Q37698921-4E4383E0-CA33-4D2E-9AD6-F44EFB2826C9 Q37705396-04C18587-A3C4-4278-8B9D-AD37DDA046DC Q37725479-5F45F222-311C-4B05-935F-F2C2A4E20953 Q37725973-C4A14A42-CD47-47A2-BC19-B23082AD2345 Q37773263-A9A58904-DD0D-48D9-8C86-810BF8EBA387 Q37941807-2B6B1C00-D73C-478D-AD8E-D192AB742F24 Q37965555-D00CC7BB-2B92-4FA2-97D9-966A62B14F9E Q38089186-76C30D96-C85C-432C-B6A1-E95FFE39DF22 Q38090680-C4D93345-3392-4EC4-9845-D3327D24B25B Q38196723-A410B334-598F-4416-9ADA-837208CDBA18 Q38852051-AE20A780-FB90-4947-9BE0-FAB110B8AF63

P2860

Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer.

http://www.wikidata.org/entity/Q34527500

description

2006 nî lūn-bûn

@nan

2006 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Phase I trial of the trifuncti ...... b in metastatic breast cancer.

@ast

Phase I trial of the trifuncti ...... b in metastatic breast cancer.

@en

Phase I trial of the trifuncti ...... b in metastatic breast cancer.

@nl

type

label

Phase I trial of the trifuncti ...... b in metastatic breast cancer.

@ast

Phase I trial of the trifuncti ...... b in metastatic breast cancer.

@en

Phase I trial of the trifuncti ...... b in metastatic breast cancer.

@nl

prefLabel

Phase I trial of the trifuncti ...... b in metastatic breast cancer.

@ast

Phase I trial of the trifuncti ...... b in metastatic breast cancer.

@en

Phase I trial of the trifuncti ...... b in metastatic breast cancer.

@nl

P1433

Q34527500-484E275D-F743-4AC1-8C26-556EC6F9F5AA

P1476

Q34527500-201FEA2F-36F7-48C8-A8C4-724DFC753793

P2093

Q34527500-1CA54B3B-63D9-4048-AC6D-C26D5B79F516

Q34527500-20DDA028-941A-4043-8609-1C041B72EC9B

Q34527500-6D01513E-6195-427B-B526-BEBCD41262BC

Q34527500-72757E5D-784C-460D-9A28-BCE1AA5F4E51

Q34527500-8B29241E-19F2-4E3F-B895-907A1BF82673

Q34527500-ADCE17FB-FCFF-46EF-B458-7E3266A269E2

Q34527500-B1EE41CA-2BF0-4BCB-9C99-8FF801822375

Q34527500-B439E7E2-4A13-43DB-AD39-042E56A6D1C5

Q34527500-D49304AB-E207-4722-BCDC-975F51B48ABA

Q34527500-E4B504DF-5089-4BC9-914D-D5ACF724ABE1

P304

Q34527500-70C53AD3-AF7A-49AF-8DAA-40177AE24867

P31

Q34527500-4618904C-FF60-4051-961F-D3BACBC113F1

P356

Q34527500-8CA2835F-3C1C-4FB3-AB26-36F965612342

P407

Q34527500-376E92AC-791A-485E-96A4-11078CA479E0

P433

Q34527500-0479B712-5E1D-4757-A9AA-657CDEA9073E

P478

Q34527500-27E4D8B4-EEF9-4700-B016-5BB11486B712

P50

Q34527500-889F9F20-8F73-454C-A846-DFE5D845EC7A

Q34527500-D52E560A-AC4B-4134-A3F4-37DB18CACA1E

P577

Q34527500-604FF264-25A2-416B-9C3E-3228048C9A87

P698

Q34527500-163A96B1-3159-4CA8-A10D-6175C523BA69

P921

Q34527500-675AA3EC-FD9C-44DC-8418-179431F161DD

Q34527500-8992F250-3473-4AB1-AE69-96F22DB11C21

P356

1078-0432.CCR-05-2436

P1433

Clinical Cancer Research

P1476

Phase I trial of the trifuncti ...... b in metastatic breast cancer.

@en

P2093

Agnieszka Korfel

http://www.w3.org/2001/XMLSchema#string

Alexander Marmé

http://www.w3.org/2001/XMLSchema#string

Brigitte Rack

http://www.w3.org/2001/XMLSchema#string

Eckhard Thiel

http://www.w3.org/2001/XMLSchema#string

Harald Sommer

http://www.w3.org/2001/XMLSchema#string

Horst Lindhofer

http://www.w3.org/2001/XMLSchema#string

Maja Heinrigs

http://www.w3.org/2001/XMLSchema#string

Michael Jäger

http://www.w3.org/2001/XMLSchema#string

Philipp Kiewe

http://www.w3.org/2001/XMLSchema#string

Steffen Kahlert

http://www.w3.org/2001/XMLSchema#string

P304

3085-3091

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-05-2436

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Alexander Marmé

P577

2006-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16707606

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial